FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2896065239> ?p ?o ?g. }

• W2896065239 endingPage "450" @default.
• W2896065239 startingPage "443" @default.
• W2896065239 abstract "To evaluate and compare the efficiency and safety of raltitrexed- or floxuridine (FUDR)-based transarterial chemoembolization (TACE) in patients with unresectable colorectal cancer liver metastasis (CRCLM). We conducted a retrospective analysis of 81 patients with unresectable CRCLM who failed systemic chemotherapy and were treated with TACE in our department from Oct 2014 to Oct 2017. Of these, 61 patients received TACE using raltitrexed, oxaliplatin, and pirarubicin (raltitrexed group), and 20 received TACE using FUDR, oxaliplatin, and pirarubicin (FUDR group). The objective response rate (ORR), disease control rate (DCR), overall survival (OS, from the first TACE), progression-free survival (PFS, from the first TACE), and adverse reactions were evaluated and compared between the two groups, and prognostic factors for OS were analyzed. The ORRs of the raltitrexed group and FUDR group were 67.2 and 45.0%, respectively (P = 0.076), and the DCRs were 86.9 and 80.0%, respectively (P = 0.452). The median OS (from first TACE) was 14.0 months in the raltitrexed group and 13.0 months in the FUDR group (P = 0.556). The median PFS (from first TACE) was 2.1 months in the raltitrexed group and 2.4 months in the FUDR group (P = 0.878). Univariate and multivariate analyses showed that the primary tumor site, Child–Pugh class, and combination with local ablation (RFA or CRA) were independent significant factors affecting survival. There were no significant differences in adverse reactions between the two groups (P > 0.05), and no treatment-related death occurred in either group. TACE treatment based on raltitrexed or FUDR is an efficient and safe alternative choice for treating unresectable CRCLM." @default.
• W2896065239 created "2018-10-26" @default.
• W2896065239 creator A5011184415 @default.
• W2896065239 creator A5019755196 @default.
• W2896065239 creator A5027541188 @default.
• W2896065239 creator A5031077714 @default.
• W2896065239 creator A5045644965 @default.
• W2896065239 creator A5070624135 @default.
• W2896065239 creator A5073136828 @default.
• W2896065239 creator A5083617730 @default.
• W2896065239 creator A5087472916 @default.
• W2896065239 creator A5088046842 @default.
• W2896065239 date "2018-10-10" @default.
• W2896065239 modified "2023-09-29" @default.
• W2896065239 title "Transarterial chemoembolization with raltitrexed-based or floxuridine-based chemotherapy for unresectable colorectal cancer liver metastasis" @default.
• W2896065239 cites W104517420 @default.
• W2896065239 cites W134118957 @default.
• W2896065239 cites W148333904 @default.
• W2896065239 cites W1907332678 @default.
• W2896065239 cites W1968181125 @default.
• W2896065239 cites W1975340808 @default.
• W2896065239 cites W1985912796 @default.
• W2896065239 cites W1996869264 @default.
• W2896065239 cites W2005348280 @default.
• W2896065239 cites W2005631828 @default.
• W2896065239 cites W2017827047 @default.
• W2896065239 cites W2036672856 @default.
• W2896065239 cites W2048690087 @default.
• W2896065239 cites W2053351683 @default.
• W2896065239 cites W2053445812 @default.
• W2896065239 cites W2072998178 @default.
• W2896065239 cites W2075612789 @default.
• W2896065239 cites W2085070000 @default.
• W2896065239 cites W2103502575 @default.
• W2896065239 cites W2104580737 @default.
• W2896065239 cites W2110519215 @default.
• W2896065239 cites W2113058626 @default.
• W2896065239 cites W2129998117 @default.
• W2896065239 cites W2149356308 @default.
• W2896065239 cites W2150459940 @default.
• W2896065239 cites W2151436951 @default.
• W2896065239 cites W2272984102 @default.
• W2896065239 cites W2311396918 @default.
• W2896065239 cites W2319358952 @default.
• W2896065239 cites W2359539481 @default.
• W2896065239 cites W2508071701 @default.
• W2896065239 cites W2591097658 @default.
• W2896065239 cites W2602536250 @default.
• W2896065239 cites W2781525129 @default.
• W2896065239 doi "https://doi.org/10.1007/s12094-018-1942-0" @default.
• W2896065239 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30306400" @default.
• W2896065239 hasPublicationYear "2018" @default.
• W2896065239 type Work @default.
• W2896065239 sameAs 2896065239 @default.
• W2896065239 citedByCount "8" @default.
• W2896065239 countsByYear W28960652392019 @default.
• W2896065239 countsByYear W28960652392020 @default.
• W2896065239 countsByYear W28960652392022 @default.
• W2896065239 countsByYear W28960652392023 @default.
• W2896065239 crossrefType "journal-article" @default.
• W2896065239 hasAuthorship W2896065239A5011184415 @default.
• W2896065239 hasAuthorship W2896065239A5019755196 @default.
• W2896065239 hasAuthorship W2896065239A5027541188 @default.
• W2896065239 hasAuthorship W2896065239A5031077714 @default.
• W2896065239 hasAuthorship W2896065239A5045644965 @default.
• W2896065239 hasAuthorship W2896065239A5070624135 @default.
• W2896065239 hasAuthorship W2896065239A5073136828 @default.
• W2896065239 hasAuthorship W2896065239A5083617730 @default.
• W2896065239 hasAuthorship W2896065239A5087472916 @default.
• W2896065239 hasAuthorship W2896065239A5088046842 @default.
• W2896065239 hasBestOaLocation W28960652391 @default.
• W2896065239 hasConcept C121608353 @default.
• W2896065239 hasConcept C126322002 @default.
• W2896065239 hasConcept C143998085 @default.
• W2896065239 hasConcept C2776694085 @default.
• W2896065239 hasConcept C2779013556 @default.
• W2896065239 hasConcept C2779268555 @default.
• W2896065239 hasConcept C2779598120 @default.
• W2896065239 hasConcept C2780456651 @default.
• W2896065239 hasConcept C2780962732 @default.
• W2896065239 hasConcept C526805850 @default.
• W2896065239 hasConcept C71924100 @default.
• W2896065239 hasConcept C90924648 @default.
• W2896065239 hasConceptScore W2896065239C121608353 @default.
• W2896065239 hasConceptScore W2896065239C126322002 @default.
• W2896065239 hasConceptScore W2896065239C143998085 @default.
• W2896065239 hasConceptScore W2896065239C2776694085 @default.
• W2896065239 hasConceptScore W2896065239C2779013556 @default.
• W2896065239 hasConceptScore W2896065239C2779268555 @default.
• W2896065239 hasConceptScore W2896065239C2779598120 @default.
• W2896065239 hasConceptScore W2896065239C2780456651 @default.
• W2896065239 hasConceptScore W2896065239C2780962732 @default.
• W2896065239 hasConceptScore W2896065239C526805850 @default.
• W2896065239 hasConceptScore W2896065239C71924100 @default.
• W2896065239 hasConceptScore W2896065239C90924648 @default.
• W2896065239 hasFunder F4320325338 @default.
• W2896065239 hasFunder F4320335777 @default.
• W2896065239 hasIssue "4" @default.

• next